It took 3 news releases to tell investors where we were at patient 184 and advise us on the phase III trial moving forward.

Please note;

- None of the releases included the actual patient count analysed ( only assumed it was 184 )

- None of the releases included the absolute efficacy to that point

- Eventually we were told 650 patient were required by the DSMB/FDA to power the trial, this number mathematically ( does math still count here Mr. Biehl III ? ) told us we were at an 11% absolute efficacy ( more than double the 5% recently offered )

- Soon after at the company AGM attended by about 8 retail holders, the CEO told us only 600 patients were required, but the company settled on 650...??? maybe the shareholders should have binn told that?

- On the back of the SAGA ( as described by our CEO at the AGM ) the company printed 43 MILLION shares at 29 CENTS and an additional 12 MILLION at 55 CENTS about 6 months later

- Is this most recent Bengalorian Buggering another "Interim Analysis SAGA" or worse...much , much worse?

Do American execs think they can completely ignore their FIDUCIARY DUTY while operating north of the border?

Time to get up off the couch and put the screws to those that have screwed us over repeatedly

Johnnyboy was right...this is a "UFO"

An Unethical F'ing Over

Sqr